Literature DB >> 27356707

Garlic Phytocompounds Possess Anticancer Activity by Specifically Targeting Breast Cancer Biomarkers - an in Silico Study.

Nabarun Roy1, Sangeetha Davis, Arunaksharan Narayanankutty, Pa Nazeem, Td Babu, Ps Abida, Pa Valsala, Achuthan C Raghavamenon.   

Abstract

BACKGROUND: Breast cancer (BC) is a serious lifestyle disease. There are several prognostic biomarkers like nuclear receptors whose over-expression is associated with BC characteristics. These biomarkers can be blocked by compounds with anti-cancer potential but selection must be made on the basis of no adverse side effects. This study is focused on finding of compounds from a plant source garlic.
MATERIALS AND METHODS: Twenty compounds from garlic and five targets considered involved in BC were retrieved from Pubchem database and Protein Data Bank respectively. They were docked using Accelrys Discovery Studio (DS) 4.0. The compounds which showed interaction were checked for drug likeliness.
RESULTS: Docking studies and ADMET evaluation revealed twelve compounds to be active against the targets. All the compounds displayed highly negative dock scores which indicated good interactions.
CONCLUSIONS: The results of this study should help researchers and scientists in the pharmaceutical field to identify drugs based on garlic.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27356707

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  3 in total

1.  Physicochemical Properties and Biological Activities of Garlic (Allium sativum L.) Bulb and Leek (Allium ampeloprasum L. var. Porrum) Leaf Oil Extracts.

Authors:  Elias Lemma; Zekeria Yusuf; Mulugeta Desta; Sultan Seyida; Megersa Idris; Sewnet Mengistu; Jemal Teneshu
Journal:  ScientificWorldJournal       Date:  2022-04-26

Review 2.  Antimicrobial properties of hydrophobic compounds in garlic: Allicin, vinyldithiin, ajoene and diallyl polysulfides.

Authors:  Masato Nakamoto; Kayo Kunimura; Jun-Ichiro Suzuki; Yukihiro Kodera
Journal:  Exp Ther Med       Date:  2019-12-27       Impact factor: 2.447

3.  Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F).

Authors:  Noeman Ardalan; Abbas Akhavan Sepahi; Ramazan Ali Khavari-Nejad
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.